Navigation Links
Platinum Underwriters Holdings, Ltd. Reports Record Fourth Quarter and Year Ended December 31, 2007 Financial Results
Date:2/19/2008

base through share repurchases, subject to appropriate valuation constraints."

Results for the quarter ended December 31, 2007 were summarized as follows:

-- Net income was $102.2 million or $1.60 per diluted common share.

-- Net premiums written were $241.0 million and net premiums earned were

$302.0 million.

-- GAAP combined ratio was 75.3%.

-- Net investment income was $53.6 million.

Results for the quarter ended December 31, 2007 compared to the quarter ended December 31, 2006 were summarized as follows:

-- Net income increased $16.2 million (or 18.9%).

-- Net premiums written decreased $34.5 million (or 12.5%) and net

premiums earned decreased $13.7 million (or 4.3%).

-- GAAP combined ratio decreased 6.0 percentage points.

-- Net investment income increased $2.7 million (or 5.4%).

Net premiums written for Platinum's Property and Marine, Casualty and Finite Risk segments for the quarter ended December 31, 2007 were $105.6 million, $128.7 million and $6.8 million, respectively, representing 43.8%, 53.4% and 2.8%, respectively, of the total net premiums written. Combined ratios for these segments were 56.8%, 91.7% and 24.6%, respectively. Compared to the quarter ended December 31, 2006, net premiums written increased $14.6 million (or 16.0%) in the Property and Marine segment and decreased $45.1 million (or 25.9%) and $4.0 million (or 37.2%) in the Casualty and Finite Risk segments, respectively.

Results for the year ended December 31, 2007 were summarized as follows:

-- Net income was $357.0 million or $5.38 per diluted common share.

-- Net premiums written were $1.12 billion and net premiums earned were

$1.17 billion.

-- GAAP combined ratio was 81.0%.

-- Net investment income was $214.2 million.

Results for the year ended December 31, 2007 compared to the year ended December 31, 2006 were summarized as foll
'/>"/>

SOURCE Platinum Underwriters Holdings, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Platinum Underwriters Holdings, Ltd. to Report Third Quarter 2007 Results on October 23, 2007
2. Disability Management Employer Coalition Names Mercer as Newest Platinum Sponsor
3. Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer
4. IncentOne Receives Incentive Platinum Partner Award
5. Light powered platinum more targeted and 80 times more powerful than similar cancer treatments
6. Study reveals why certain ovarian cancers develop resistance to platinum-based chemotherapy
7. AMN Healthcare Services Acquires Platinum Select
8. Hooper Holmes to Exhibit at the 2007 Sixth Annual Association of Home Office Underwriters Conference
9. Pharmassets Underwriters Release Shares from Lock-Up
10. Darwin Professional Underwriters, Inc. Reports Record Net Income of $8.4 Million for the Third Quarter
11. Specialty Underwriters Alliance to Present at 2007 FBR Capital Markets Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...alth-related Questions for Tonight,s,Presidential ...- WebMD, the leading source of,health information,...ial,candidates, proposed health care policies, loc...t the candidates, stance on health insurance, medi... public health issues., The in-depth coverage is ...
(Date:10/7/2008)...PRNewswire-USNewswire/ -- The Ohio Nurses,Associat...ced today its,final round of endorsed candidates f...o Senate:, SD 26 Karen Gillmor (R) Tiffin, Ohio ...(R) Grove City;, HD 28 Connie Pillich (D) Cincinn...These ONA-endorsed candidates for the Ohio General...
(Date:10/7/2008)...wswire-USNewswire/ -- Kristi Yamaguchi, Olympic,Go... the Stars, has been,named chairperson for the 200...gn in an effort to help raise funds in support of ...e and promote lung health., The American Lung Ass...o conquer Tuberculosis. Today, the Lung Associatio...
(Date:10/7/2008)...ar to more expensive whole-leg color ultrasound, ...lthDay News) -- An older, simpler test to look for...osis, or DVT -- is as effective as a newer, more e...searchers found that 2-point ultrasonography of th...trasound -- was as good at detecting DVT as the ne...
Breaking Medicine News(10 mins):Health News:WebMD Highlights Presidential Candidates' Views on Health Care 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 3Health News:Kristi Yamaguchi Chairs American Lung Association Christmas Seals Campaign 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3
...e aged men who would like to grow old in good heal... education, and a wife, according to a recent stud...ican men living in the US state of Hawaii revealed...edictors of which middle-aged men would live healt...
...lergic reaction has been widely reported by women ... associated with burning in their groin and genita...onfirmed by doctors as a true case of allergy that...ankfully doctors have given the hope to such women...
...than 80,000 people in the United States are on wai...o wait for the death of a matching donor, but more...g donors. Last year nearly 7,000 people donated a...of a lung to help someone in need of a transplant....
...enes of progeny are dependant on a fairly simple f...potent enough to impact the genes of the future ge...hers, supplements consumed by expectant mice were ...s. The findings appear in the Proceedings of the N...
Other Medicine News:Health News:Keys to Good Health in Old Age Begins in Midlife 2Health News:See, men cause allergies in women after sex 2Health News:Researchers Study Reimbursing Living Organ Donors for Out-of-Pocket Expenses 2Health News:Researchers Study Reimbursing Living Organ Donors for Out-of-Pocket Expenses 3
(Date:10/7/2008)...e-FirstCall/ - Burcon NutraScience,Corporation (TS...Supertein(TM) canola protein isolates are GRAS (Ge... in a variety of food and beverage,applications. T...n,independent evaluation by a panel of qualified e...utritional sciences, food allergies and pediatric,...
(Date:10/7/2008)...at ACG Annual Scientific Meeting -, ORLANDO, Fla....ceuticals, Inc. (formerly Microbia, Inc.) and Fore...d the presentation of results from a Phase,2b stud...20 patients with,irritable bowel syndrome with con...that once- daily oral dosing of linaclotide, acros...
(Date:10/7/2008)...e-FirstCall/ -- Ardea Biosciences, Inc.,(Nasdaq: ...A119, a Potent,and Highly Selective MEK1/2 Inhibit...- induced Chronic Colitis in Mice," was presented ...2008 Annual Meeting in Orlando,Florida. The poste...,RDEA119, the Company,s lead mitogen-activated ERK...
(Date:10/6/2008)...ewswire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq: V... joining the,Company as Vice President of Investor... will be responsible for all investor relations,fu...l Officer Kurt,Leutzinger., Most recently, Dr. Sm...Analyst at JPMorgan Securities, and has been an an...
Breaking Medicine Technology:Burcon announces GRAS status for Puratein(R) & Supertein(TM) 2Burcon announces GRAS status for Puratein(R) & Supertein(TM) 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 2Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 3New Drug Application for Tolvaptan Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia Accepted by the U S Fo 2362 1New Drug Application for Tolvaptan Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia Accepted by the U S Fo 2362 2New Drug Application for Tolvaptan Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia Accepted by the U S Fo 2362 3Senesco Technologies Closes on Additional 244 0 Million of Previously Announced Financing 2360 1Senesco Technologies Closes on Additional 244 0 Million of Previously Announced Financing 2360 2Senesco Technologies Closes on Additional 244 0 Million of Previously Announced Financing 2360 3Supplemental New Drug Application for PREZISTA 28TM 29 Submitted to U S Food and Drug Administration 1117 1Supplemental New Drug Application for PREZISTA 28TM 29 Submitted to U S Food and Drug Administration 1117 2Supplemental New Drug Application for PREZISTA 28TM 29 Submitted to U S Food and Drug Administration 1117 3Supplemental New Drug Application for PREZISTA 28TM 29 Submitted to U S Food and Drug Administration 1117 4Supplemental New Drug Application for PREZISTA 28TM 29 Submitted to U S Food and Drug Administration 1117 5FDA to Extend Review of Data Quality Submission for Genasense 28R 29 in Melanoma 1115 1FDA to Extend Review of Data Quality Submission for Genasense 28R 29 in Melanoma 1115 2FDA to Extend Review of Data Quality Submission for Genasense 28R 29 in Melanoma 1115 3
...a Trial to 9 mg Dosage,Level, HOPKINTON, Mass., Ap... Sciences announced today that clinical data on it...ented in the Neurotrauma,and Critical Care Scienti...ican Association of Neurological Surgeons (AANS) i...s of the Cethrin Phase I/IIa,Prospective Clinical ...
...ire-FirstCall/ -- Kosan,Biosciences Incorporated t...t-generation epothilone, showing a high level of,a...and safety,profile in a broad range of in vitro te...hemically engineered to have a favorable,tissue di... to,result in excellent tumor penetration and a lo...
Other Medicine Technology:Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase,I/IIa 6-Month Results at 75th Annual Meeting of the American,Association of Neurological Surgeons 2Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase,I/IIa 6-Month Results at 75th Annual Meeting of the American,Association of Neurological Surgeons 3Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase,I/IIa 6-Month Results at 75th Annual Meeting of the American,Association of Neurological Surgeons 4Kosan Presents Preclinical Antitumor and Safety Data On,Next-Generation Epothilone KOS-1803 at AACR 2Kosan Presents Preclinical Antitumor and Safety Data On,Next-Generation Epothilone KOS-1803 at AACR 3
... of deflectable curve catheters designed to specif...r patients with small anatomies. Each catheter is ... the finest materials. A unique multi-step process...ion technologies results in the excellent torque a...
... of fixed curve catheters designed to specifically...ents with small anatomies. Each catheter is handcr...inest materials. A unique multi-step process that ...chnologies results in the excellent torque and fle...
4Fr, 5Fr & 6Fr diagnostic electrophysiology catheters with fixed curves.
Inquiry 4Fr, 5Fr and 6Fr diagnostic electrophysiology catheters offer simple, precise distal control with it's patented Easy-Hand steering mechanism.
Medicine Products: